Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Haematological cancer

A step before the next leap?

Nature Reviews Clinical Oncology volume 10, pages 610–612 (2013)Cite this article

Subjects

The survival of patients with multiple myeloma has improved tremendously over the years. However, patients with disease that has relapsed and is refractory to thalidomide, lenalidomide and bortezomib have poor long-term outcomes. The novel immunomodulatory drug pomalidomide now offers a new therapeutic option for these patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Kumar, S. K. et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 26, 149–157 (2012).

    Article  CAS  Google Scholar 

  2. Siegel, D. S. et al. Long-term safety and efficacy of pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in relapsed and refractory multiple myeloma (RRMM) patients enrolled in the MM-002 phase II trial [abstract]. J. Clin. Oncol. 31 (Suppl.), a8588 (2013).

    Google Scholar 

  3. San Miguel, J. et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. http://dx.doi.org/10.1016/S1470-2045(13)70380-2.

  4. Schey, S. A. et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J. Clin. Oncol. 22, 3269–3276 (2004).

    Article  CAS  Google Scholar 

  5. Lacy, M. Q. et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J. Clin. Oncol. 27, 5008–5014 (2009).

    Article  CAS  Google Scholar 

  6. Richardson, P. G. et al. Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood 121, 1961–1967 (2013).

    Article  CAS  Google Scholar 

  7. Leleu, X. et al. Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02. Blood 121, 1968–1975 (2013).

    Article  CAS  Google Scholar 

  8. US National Library of Medicine. ClinicalTrials.gov [online], (2013).

  9. US National Library of Medicine. ClinicalTrials.gov [online], (2013).

  10. Lonial, S. et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J. Clin. Oncol. 30, 1953–1959 (2012).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Washington University, School of Medicine, Section of BMT and Leukemia, Campus Box 8007, 660 South Euclid Avenue, Saint Louis, 63110, MO, USA

    Ravi Vij

Authors
  1. Ravi Vij
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Ravi Vij.

Ethics declarations

Competing interests

R. Vij is a consultant for Bristol-Myers Squibb, Celgene Corporation, Eli Lilly and Onyx Pharmaceuticals, has received honoraria from Celgene Corporation, Millennium Pharmaceuticals and Onyx Pharmaceuticals, and financial support from Celgene Corporation and Onyx Pharmaceuticals.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vij, R. A step before the next leap?. Nat Rev Clin Oncol 10, 610–612 (2013). https://doi.org/10.1038/nrclinonc.2013.181

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrclinonc.2013.181

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing